Olaparib induced aplastic anemia in a patient with castrate resistant prostate cancer: A case report
Olaparib is (ADP‐ribose) polymerase inhibitor (PARPi), which stops the repair of single-stranded DNA breaks. This leads to the death of cancer cells with BRCA1/BRCA2 mutations or homologous recombination deficiency. Since being approved by the FDA in 2023 for treating castrate-resistant prostate can...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Leukemia Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213048924000633 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850174664820654080 |
|---|---|
| author | Elrazi A Ali Monika Jain Akriti Pokhrel Unni Mooppan Jen chin Wang |
| author_facet | Elrazi A Ali Monika Jain Akriti Pokhrel Unni Mooppan Jen chin Wang |
| author_sort | Elrazi A Ali |
| collection | DOAJ |
| description | Olaparib is (ADP‐ribose) polymerase inhibitor (PARPi), which stops the repair of single-stranded DNA breaks. This leads to the death of cancer cells with BRCA1/BRCA2 mutations or homologous recombination deficiency. Since being approved by the FDA in 2023 for treating castrate-resistant prostate cancer (CRPC), there have been some reports of myelodysplastic syndrome (MDS) and acute leukemia linked to PARP inhibitor use for ovarian, breast, pancreatic and breast cancers, there have been no reports of aplastic anemia after receiving PARPi therapy. This case report describes a 75-year-old man with BRCA2-positive metastatic castrate-resistant prostate cancer who developed aplastic anemia after taking olaparib. |
| format | Article |
| id | doaj-art-ad81d50f742f4b2eb0f8f638fe04ccae |
| institution | OA Journals |
| issn | 2213-0489 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Leukemia Research Reports |
| spelling | doaj-art-ad81d50f742f4b2eb0f8f638fe04ccae2025-08-20T02:19:37ZengElsevierLeukemia Research Reports2213-04892024-01-012210047310.1016/j.lrr.2024.100473Olaparib induced aplastic anemia in a patient with castrate resistant prostate cancer: A case reportElrazi A Ali0Monika Jain1Akriti Pokhrel2Unni Mooppan3Jen chin Wang4Internal Medicine Department, Interfaith Medical Center, One Brooklyn Health, Brooklyn, NY, USAInternal Medicine Department, Interfaith Medical Center, One Brooklyn Health, Brooklyn, NY, USADepartment of Hematology and Medical Oncology, Brookdale University Hospital Medical Center, One Brooklyn Health, Brooklyn, NY, USADepartment of Urology, Brookdale University Hospital Medical Center, One Brooklyn Health, Brooklyn, NY 11212, USADepartment of Hematology and Medical Oncology, Brookdale University Hospital Medical Center, One Brooklyn Health, Brooklyn, NY, USA; Corresponding author.Olaparib is (ADP‐ribose) polymerase inhibitor (PARPi), which stops the repair of single-stranded DNA breaks. This leads to the death of cancer cells with BRCA1/BRCA2 mutations or homologous recombination deficiency. Since being approved by the FDA in 2023 for treating castrate-resistant prostate cancer (CRPC), there have been some reports of myelodysplastic syndrome (MDS) and acute leukemia linked to PARP inhibitor use for ovarian, breast, pancreatic and breast cancers, there have been no reports of aplastic anemia after receiving PARPi therapy. This case report describes a 75-year-old man with BRCA2-positive metastatic castrate-resistant prostate cancer who developed aplastic anemia after taking olaparib.http://www.sciencedirect.com/science/article/pii/S2213048924000633Aplastic anemiaOlaparibProstate cancerPancytopenia |
| spellingShingle | Elrazi A Ali Monika Jain Akriti Pokhrel Unni Mooppan Jen chin Wang Olaparib induced aplastic anemia in a patient with castrate resistant prostate cancer: A case report Leukemia Research Reports Aplastic anemia Olaparib Prostate cancer Pancytopenia |
| title | Olaparib induced aplastic anemia in a patient with castrate resistant prostate cancer: A case report |
| title_full | Olaparib induced aplastic anemia in a patient with castrate resistant prostate cancer: A case report |
| title_fullStr | Olaparib induced aplastic anemia in a patient with castrate resistant prostate cancer: A case report |
| title_full_unstemmed | Olaparib induced aplastic anemia in a patient with castrate resistant prostate cancer: A case report |
| title_short | Olaparib induced aplastic anemia in a patient with castrate resistant prostate cancer: A case report |
| title_sort | olaparib induced aplastic anemia in a patient with castrate resistant prostate cancer a case report |
| topic | Aplastic anemia Olaparib Prostate cancer Pancytopenia |
| url | http://www.sciencedirect.com/science/article/pii/S2213048924000633 |
| work_keys_str_mv | AT elraziaali olaparibinducedaplasticanemiainapatientwithcastrateresistantprostatecanceracasereport AT monikajain olaparibinducedaplasticanemiainapatientwithcastrateresistantprostatecanceracasereport AT akritipokhrel olaparibinducedaplasticanemiainapatientwithcastrateresistantprostatecanceracasereport AT unnimooppan olaparibinducedaplasticanemiainapatientwithcastrateresistantprostatecanceracasereport AT jenchinwang olaparibinducedaplasticanemiainapatientwithcastrateresistantprostatecanceracasereport |